Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972716 | 0.84 | NCF1 (0.45) | GBA1NCF1HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL26615637 | 0.83 | GBA1 (0.38) | GBA1HSD11B1OPRM1 | |
| SCHEMBL14751750 | 0.80 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL20888184 | 0.80 | GBA1 (0.46) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL24658661 | 0.79 | CYP2D6 (0.38) | NCF1CYP2D6 | |
| SCHEMBL11971970 | 0.79 | NCF1 (0.54) | GBA1NCF1HSD11B1 | |
| SCHEMBL20888183 | 0.78 | GBA1 (0.44) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL19399848 | 0.78 | GBA1 (0.44) | GBA1HSD11B1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL24658419 | 0.78 | NCF1 (0.33) | NCF1 | |
| SCHEMBL11972565 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022173756-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2013036665-A1 | COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013036669-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | GBA1 3713/4885NCF1 849/4885HSD11B1 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.